Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 3, 2004, Pages 844-850

  Lu, Bo ^a   Geng, Ling ^a   Musiek, Amy ^a   Tan, Jiahui ^a   Cao, Carolyn ^a   Donnelly, Edwin ^a   McMahon, Gerald ^b   Choy, Hak ^a   Hallahan, Dennis E ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b SUGEN INC   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Akt; Angiogenesis; Cell survival; Radiotherapy; SU6668

Indexed keywords

BLOOD; CELLS; IRRADIATION; RADIOTHERAPY; TUMORS;

RECEPTOR TYROSINE KINASES (RTK); TUMOR GROWTH;

ONCOLOGY;

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; IRRADIATION; LUNG CARCINOMA; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

EID: 1242293097     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.10.049     Document Type: Article

References (36)

1. Goldkorn T., Balaban N., Shannon M., et al. EGF receptor phosphorylation is affected by ionizing radiation. Biochim Biophys Acta. 1358:1997;289-299.
2. Bowers G., Reardon D., Hewitt T., et al. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene. 20:2001;1388-1397.
3. Contessa J.N., Hampton J., Lammering G., et al. Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene. 21:2002;4032-4041.
4. Reardon D.B., Contessa J.N., Mikkelsen R.B., et al. Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene. 18:1999;4756-4766.
5. Dent P., Reardon D.B., Park J.S., et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell. 10:1999;2493-2506.
6. Lammering G., Hewit T.H., Hawkins W.T., et al. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst. 93:2001;921-929.
7. Geng L., Donnelly E., McMahon G., et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61:2001;2413-2419.
8. Edwards E., Geng L., Tan J., et al. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 62:2002;4671-4677.
9. Klippel A., Kavanaugh W.M., Pot D., et al. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol Cell Biol. 17:1997;338-344.
10. Andjelkovic M., Alessi D.R., Meier R., et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem. 272:1997;31515-31524.
11. Alessi D.R., Deak M., Casamayor A., et al. 3-Phosphoinositide-dependent protein kinase-1 (PDK1) Structural and functional homology with the Drosophila DSTPK61 kinase . Curr Biol. 7:1997;776-789.
12. Gerber H.P., McMurtrey A., Kowalski J., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 273:1998;30336-30343.
13. Matsui T., Li L., del Monte F., et al. Adenoviral gene transfer of activated phosphatidylinositol 3′-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation. 100:1999;2373-2379.
14. Korff T., Augustin H.G. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol. 143:1998;1341-1352.
15. Fujio Y., Guo K., Mano T., et al. Cell cycle withdrawal promotes myogenic induction of Akt, a positive modulator of myocyte survival. Mol Cell Biol. 19:1999;5073-5082.
16. Dunn I.F., Heese O., Black P.M. Growth factors in glioma angiogenesis FGFs, PDGF, EGF, and TGFs . J Neurooncol. 50:2000;121-137.
17. Fuks Z., Persaud R.S., Alfieri A., et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res. 54:1994;2582-2590.
18. Seghezzi G., Patel S., Ren C.J., et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries An autocrine mechanism contributing to angiogenesis . J Cell Biol. 141:1998;1659-1673.
19. Tsai J.C., Goldman C.K., Gillespie G.Y. Vascular endothelial growth factor in human glioma cell lines Induced secretion by EGF, PDGF-BB, and bFGF . J Neurosurg. 82:1995;864-873.
20. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59:1999;3374-3378.
21. Witte L., Fuks Z., Haimovitz-Friedman A., et al. Effects of irradiation on the release of growth factors from cultured bovine, porcine, and human endothelial cells. Cancer Res. 49:1989;5066-5072.
22. Prewett M., Huber J., Li Y., et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59:1999;5209-5218.
23. Mauceri H.J., Hanna N.N., Beckett M.A., et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 394:1998;287-291.
24. Staba M.J., Mauceri H.J., Kufe D.W., et al. R. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 5:1998;293-300.
25. Hallahan D.E., Staba-Hogan M.J., Virudachalam S., et al. X-ray-induced P-selectin localization to the lumen of tumor blood vessels. Cancer Res. 58:1998;5216-5220.
26. Advani S.J., Sibley G.S., Song P.Y., et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation A new paradigm for destruction of therapeutically intractable tumors . Gene Ther. 5:1998;160-165.
27. Hallahan D.E., Mauceri H.J., Seung L.P., et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med. 1:1995;786-791.
28. Kruskal W.H., Wallis W.A. Use of ranks in one-criteria variance analysis. J Am Stat Assoc. 47:1952;583-621.
29. Laird A.D., Christensen J.G., Li G., et al. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J. 16:2002;681-690.
30. Shaheen R.M., Davis D.W., Liu W., et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 59:1999;5412-5416.
31. Laird A.D., Vajkoczy P., Shawver L.K., et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 60:2000;4152-4160.
32. Ning S., Laird D., Cherrington J.M., et al. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res. 157:2002;45-51.
33. Bergers G., Song S., Meyer-Morse N., et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 111:2003;1287-1295.
34. Schueneman A.J., Himmelfarb E., Geng L., et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63:2003;4009-4016.
35. Hahnfeldt P., Folkman J., Hlatky L. Minimizing long-term tumor burden The logic for metronomic chemotherapeutic dosing and its antiangiogenic basis . J Theor Biol. 220:2003;545-554.
36. Wachsberger P., Burd R., Dicker A.P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents Exploring mechanisms of interaction . Clin Cancer Res. 9:2003;1957-1971.